MB-105 is under clinical development by Mustang Bio and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MB-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MB-105 overview

MB-105 is under development for the treatment of metastatic castration resistant prostate cancer, pancreatic cancer, gastric cancer, and bladder cancer. The therapeutic candidate comprises of autologous T lymphocytes targeting prostate stem cell antigen (PSCA) and CD19 which is done by virus to insert piece of DNA in immune cells. It is developed based on PSCA CAR T technology (PSCA technology).

Mustang Bio overview

Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.

For a complete picture of MB-105’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.